Pimavanserin: a novel therapeutic approach to treat Parkinson’s Disease Psychosis
Abstract
PDP (Parkinson's disease psychosis) is a neuropsychological nonmotor manifestation that occurs in individuals as a result of Parkinsonism with the advancement of the disease. It is mainly characterized by delusions, hallucinations, and other cognitive features affecting the patient’s quality of life. Although the existing treatments for PDP have a lot of clinical experience, they focus mainly on reducing and regulating the cognitive features. Hence, it is difficult to minimize the exacerbation of motor dysfunction along with the existing motor complications of Parkinson's disease (PD). Previous medications also led to tremors and rigidity as undesirable effects with long-term use by blocking dopamine (D2) receptors. Moreover, patients with PD take several drugs to manage their motor symptoms, which may complicate their medication regimen, causing patient burden. Therefore, as an emergent pharmacotherapeutic approach, pimavanserin, which is a selective 5-HT2A receptor inverse agonist, shows promising benefits in managing disease conditions by reducing psychosis while avoiding motor worsening and other non-motor side effects. This distinguishes pimavanserin from other available therapies for PDP. This review analyzes all the previously and recently published research works that have evaluated the efficacy of pimavanserin in the clinical management of PDP with its screening and pharmacological properties.
Keywords: Pimavanserin, Parkinson's disease psychosis, 5HT2A inverse agonist, Parkinson's disease, psychotic disorders, psychosis
Keywords:
Pimavanserin, Parkinson's disease psychosis, , 5HT2A inverse agonist, Parkinson's disease, psychotic disorders, psychosisDOI
https://doi.org/10.22270/jddt.v15i12.7477References
1. Rose O, Huber S, Trinka E, et al, Treatment of Parkinson’s Disease Psychosis—A systematic review and multi-methods approach, Biomedicines, 2024; 12(10):2317. https://doi.org/10.3390/biomedicines12102317
2. Cattaneo C, Kulisevsky J, The effects of safinamide in Chinese and non-Chinese patients with Parkinson's disease, Advances in Therapy, 2024; 41(2):638-648. https://doi.org/10.1007/s12325-023-02736-2
3. Hermanowicz N, Edwards K, Parkinson's disease psychosis: symptoms, management, and economic burden, American Journal of Managed Care, 2015; 21(10 Suppl):S199-206.
4. Isaacson SH, Ballard CG, Kreitzman DL, et al, Open-label extension study of pimavanserin in Parkinson’s disease psychosis, Parkinsonism and Related Disorders, 2021; 87:25-31. https://doi.org/10.1016/j.parkreldis.2021.04.012
5. Espay AJ, Guskey MT, Norton JC, et al, Pimavanserin for Parkinson's disease psychosis: effects stratified by baseline cognition and use of cognitive-enhancing medications, Movement Disorders, 2018; 33(11):1769-1776. https://doi.org/10.1002/mds.27488
6. Isaacson SH, Coate B, Norton J, Stankovic S, Blinded SAPS-PD assessment after 10 weeks of pimavanserin treatment for Parkinson's disease psychosis, Journal of Parkinson’s Disease, 2020; 10(4):1389-1396. https://doi.org/10.3233/JPD-202047
7. Stahl SM, Parkinson’s disease psychosis as a serotonin–dopamine imbalance syndrome, CNS Spectrums, 2016; 21(5):355-359. https://doi.org/10.1017/S1092852916000602
8. Perez-Lloret S, Barrantes FJ, Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease, NPJ Parkinson’s Disease, 2016; 2:16001. https://doi.org/10.1038/npjparkd.2016.1
9. Pham Nguyen T, Abraham DS, Thibault D, et al, Low continuation of antipsychotic therapy in Parkinson disease – intolerance, ineffectiveness, or inertia?, BMC Neurology, 2021; 21:240. https://doi.org/10.1186/s12883-021-02265-x
10. Tariot PN, Cummings JL, Soto-Martin ME, et al, Trial of pimavanserin in dementia-related psychosis, New England Journal of Medicine, 2021; 385(4):309-319. https://doi.org/10.1056/NEJMoa2034634
11. Alva G, Cubała WJ, Berrio A, et al, Safety profile of pimavanserin therapy in elderly patients with neurodegenerative disease-related neuropsychiatric symptoms: a phase 3B study, Journal of Alzheimer’s Disease, 2024; 98(1):265-274. https://doi.org/10.3233/JAD-231167
12. Hacksell U, Burstein ES, McFarland K, et al, On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis, Neurochemical Research, 2014; 39(10):2008-2017. https://doi.org/10.1007/s11064-014-1293-3
13. Ballard CG, Kreitzman DL, Isaacson S, et al, Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis, Parkinsonism and Related Disorders, 2020; 77:100-106. https://doi.org/10.1016/j.parkreldis.2020.06.026
14. Goldman JG, Holden S, Treatment of psychosis and dementia in Parkinson's disease, Current Treatment Options in Neurology, 2014; 16(3):281. https://doi.org/10.1007/s11940-013-0281-2
15. Weintraub D, Chiang C, Kim HM, et al, Association of antipsychotic use with mortality risk in patients with Parkinson disease, JAMA Neurology, 2016; 73(5):535-541. https://doi.org/10.1001/jamaneurol.2016.0031
16. Stahl SM, Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors, CNS Spectrums, 2016; 21(4):271-275. https://doi.org/10.1017/S1092852916000407
17. Ridler K, Rizzo G, Burstein ES, et al, Imaging the 5-HT2C receptor with PET: Evaluation of 5-HT2C and 5-HT2A affinity of pimavanserin in the primate brain, Journal of Cerebral Blood Flow & Metabolism, 2025; 45(2):352-364. https://doi.org/10.1177/0271678X241276312
18. Zhang S, Ma Y, Emerging role of psychosis in Parkinson's disease: from clinical relevance to molecular mechanisms, World Journal of Psychiatry, 2022; 12(9):1127-1140. https://doi.org/10.5498/wjp.v12.i9.1127
19. Rissardo JP, Durante Í, Sharon I, Fornari Caprara AL, Pimavanserin and Parkinson’s disease psychosis: a narrative review, Brain Sciences, 2022; 12(10):1286. https://doi.org/10.3390/brainsci12101286
20. Pourhamzeh M, Moravej FG, Arabi M, Shahriari E, Mehrabi S, Ward R, et al, The roles of serotonin in neuropsychiatric disorders, Cellular and Molecular Neurobiology, 2022; 42:1671-1692. https://doi.org/10.1007/s10571-021-01064-9
21. Gaitonde SA, Avet C, de la Fuente Revenga M, et al, Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor, Molecular Psychiatry, 2024; 29:2753-2764. https://doi.org/10.1038/s41380-024-02531-7
22. Pahwa R, Isaacson SH, Small GW, et al, Screening, diagnosis, and management of Parkinson’s disease psychosis: recommendations from an expert panel, Neurology and Therapy, 2022; 11:1571-1582. https://doi.org/10.1007/s40120-022-00388-y
23. Sabbagh M, Small GW, Isaacson SH, et al, Unmet needs in the diagnosis and treatment of Parkinson’s disease psychosis and dementia-related psychosis, International Journal of Psychiatry in Clinical Practice, 2022; 27(1):69-81. https://doi.org/10.1080/13651501.2022.2058406
24. Chaudhuri KR, Martinez-Martin P, Brown RG, et al, The metric properties of a novel non-motor symptoms scale for Parkinson's disease, Movement Disorders, 2007; 22(13):1901-1911. https://doi.org/10.1002/mds.21596
25. Goetz CG, Tilley BC, Shaftman SR, et al, MDS-UPDRS: scale presentation and clinimetric testing results, Movement Disorders, 2008; 23(15):2129-2170. https://doi.org/10.1002/mds.22340
26. Hubbard D, Hacksell U, McFarland K, Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease psychosis, Behavioral Pharmacology, 2013; 24(7):628-632. https://doi.org/10.1097/FBP.0b013e3283656db6
27. Vanover KE, Weiner DM, Makhay M, et al, Pharmacological and behavioral profile of ACP-103, a novel 5-HT2A receptor inverse agonist, Journal of Pharmacology and Experimental Therapeutics, 2006; 317(2):910-918. https://doi.org/10.1124/jpet.105.097006
28. Vanover KE, Robbins-Weilert D, Wilbraham DG, et al, Pharmacokinetics, tolerability, and safety of ACP-103 in healthy volunteers, Journal of Clinical Pharmacology, 2007; 47(6):704-714. https://doi.org/10.1177/0091270007299431
29. Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, et al, Pimavanserin for the treatment of Parkinson's disease psychosis, Neuropsychopharmacology, 2010; 35(4):881-892. https://doi.org/10.1038/npp.2009.176
30. Cummings J, Isaacson S, Mills R, et al, Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial, Lancet, 2014; 383(9916):533-540. https://doi.org/10.1016/S0140-6736(13)62106-6
31. Abler V, Brain C, Ballard C, et al, Motor- and cognition-related safety of pimavanserin in Parkinson's disease psychosis, Frontiers in Neurology, 2022; 13:919778. https://doi.org/10.3389/fneur.2022.919778
32. Weintraub D, Espay AJ, Sharma VD, et al, Pimavanserin for psychosis in Parkinson's disease dementia: subgroup analysis of the HARMONY trial, Parkinsonism and Related Disorders, 2024; 119:105951. https://doi.org/10.1016/j.parkreldis.2023.105951
33. Friedman JH, Pimavanserin for Parkinson's disease psychosis, Expert Opinion on Pharmacotherapy, 2013; 14(14):1969-1975. https://doi.org/10.1517/14656566.2013.819345
34. McFarland K, Price DL, Bonhaus DW, Pimavanserin reverses psychosis-like behaviors in a rodent model of Parkinson's disease, Behavioral Pharmacology, 2011; 22(7):681-692. https://doi.org/10.1097/FBP.0b013e32834aff98
35. Mansuri Z, Reddy A, Vadukapuram R, et al, Pimavanserin in the treatment of Parkinson's disease psychosis: meta-analysis, Innovations in Clinical Neuroscience, 2022; 19(1-3):46-51.
36. Alipour-Haris G, Armstrong MJ, Okun M, Brown JD, Comparison of pimavanserin vs. quetiapine for hospitalization and mortality in PDP, Movement Disorders Clinical Practice, 2023; 10(3):406-414. https://doi.org/10.1002/mdc3.13652
37. Brown JD, Cicali B, Henriksen C, et al, Mortality with pimavanserin in Parkinson disease psychosis, Journal of Managed Care & Specialty Pharmacy, 2021; 27(6):785-790. https://doi.org/10.18553/jmcp.2021.27.6.785
Published
Abstract Display: 181 
PDF Downloads: 93 PDF Downloads: 21 How to Cite
Issue
Section
Copyright (c) 2025 Lavanya K, Priyanka Pinto , Manjari Sharma
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.